Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:45:10 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:VYGR - VOYAGER THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VYGR - Q0.17.50·7.831.07.55-0.19-2.51,015.37,4635,2097.74  7.88  7.5114.3398  6.06Apr 18Apr 1615 min RT 2¢

Recent Trades - Last 10 of 5209
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
2024-03-26 16:01U:VYGRNews ReleaseVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
2024-02-28 16:01U:VYGRNews ReleaseVoyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2024-02-26 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
2024-02-21 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
2024-02-20 07:00U:VYGRNews ReleaseVoyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer ¢ € ™s Disease and Advances Program into Late Research
2024-02-07 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
2024-01-04 22:46U:VYGRNews ReleaseVoyager Therapeutics Announces Pricing of Public Offering
2024-01-04 16:14U:VYGRNews ReleaseVoyager Therapeutics Announces Proposed Public Offering
2024-01-03 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 07:00U:VYGRNews ReleaseVoyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
2023-12-06 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
2023-11-06 16:01U:VYGRNews ReleaseVoyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
2023-10-30 07:00U:VYGRNews ReleaseVoyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
2023-09-25 07:00U:VYGRNews ReleaseVoyager Therapeutics to Present at the Chardan Genetic Medicines Conference
2023-09-07 16:01U:VYGRNews ReleaseVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-30 07:00U:VYGRNews ReleaseVoyager Therapeutics to Participate in Upcoming Investor Conferences
2023-08-08 16:01U:VYGRNews ReleaseVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-07 08:00U:VYGRNews ReleaseVoyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer